Clinical Trials: Clinical Trial Logistics

Inventory Management in Clinical Trial Logistics

Posted on digi By digi

Inventory management in clinical trials goes beyond stock tracking—it ensures investigational medicinal products (IMPs), comparators, and ancillary supplies are available, reconciled, and compliant with regulatory expectations. For US sponsors, the FDA requires meticulous inventory records under 21 CFR Part 312. Poor inventory control can lead to stockouts, overages, and reconciliation gaps, each of which compromises patient safety, data integrity, and inspection readiness.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Chain of Custody in Clinical Trial Logistics

Posted on digi By digi

Chain of custody (CoC) refers to the documented and unbroken trail showing the movement and handling of investigational medicinal products (IMPs) from manufacturer to depot, site, and ultimately the patient. For US sponsors, the FDA requires that every transfer of custody is recorded, ensuring accountability, product integrity, and patient safety. Inadequate custody documentation can result in Form 483s, warning letters, and, in some cases, trial suspension.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Labeling Compliance in Clinical Trial Logistics

Posted on digi By digi

Labeling is a high-risk compliance area in clinical trial logistics. Incorrect or incomplete labels can compromise blinding, patient safety, and regulatory approval. For US sponsors, the FDA requires investigational products (IMPs) to be labeled in accordance with 21 CFR Part 312 and 21 CFR Part 211. Beyond FDA, EMA GDP, ICH GCP, and WHO guidelines also impose strict labeling requirements. Errors in trial labeling frequently result in FDA Form 483 observations and trial delays.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Import/Export Compliance in Clinical Trial Logistics

Posted on digi By digi

Clinical trial logistics frequently require cross-border shipments of investigational medicinal products (IMPs), comparators, and ancillary supplies. Each movement involves customs clearance, regulatory permits, and strict documentation. For US sponsors, failure to comply with import/export requirements can lead to shipment delays, trial suspension, and FDA citations under 21 CFR Part 312. Compliance failures also risk patient safety and data integrity when dosing schedules are interrupted.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Temperature Monitoring in Clinical Trial Logistics

Posted on digi By digi

Temperature monitoring ensures investigational medicinal products (IMPs) remain within approved storage and transport conditions from manufacture to patient administration. For US sponsors, failure to maintain adequate monitoring is a common cause of Form 483s and trial delays. FDA requires sponsors to ensure that temperature-sensitive drugs, particularly biologics, are stored and shipped within validated ranges. Deviations can compromise patient safety and data integrity.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Comparator Sourcing in Clinical Trial Logistics

Posted on digi By digi

Comparator sourcing is one of the most complex aspects of clinical trial logistics. Comparators—commercially available drugs used for comparison with investigational products (IMPs)—are essential in demonstrating efficacy and safety in randomized controlled trials. For US sponsors, FDA oversight of comparator sourcing ensures the authenticity, quality, and regulatory compliance of the comparator supply chain. Failures in comparator sourcing can result in delayed trial initiation, regulatory citations, and jeopardized trial outcomes.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Direct-to-Patient (DTP) Logistics in Clinical Trials

Posted on digi By digi

Direct-to-Patient (DTP) logistics—delivering investigational medicinal products (IMPs) directly to patients’ homes—has emerged as a cornerstone of decentralized clinical trials (DCTs). For US sponsors, the FDA has increasingly focused on DTP oversight due to risks in chain of custody, temperature control, and accountability. While DTP models improve patient convenience and recruitment, they also introduce compliance challenges, requiring meticulous planning, vendor oversight, and regulatory alignment.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Returns and Destruction of Investigational Products in Clinical Trial Logistics

Posted on digi By digi

The management of investigational medicinal product (IMP) returns and destruction is a critical component of clinical trial logistics. Improper handling of unused, expired, or damaged IMPs can result in data integrity issues, regulatory non-compliance, and patient safety risks. For US sponsors, FDA requires documented accountability of IMPs throughout their lifecycle, including return to depots and destruction under controlled conditions. Failures in this area often result in FDA Form 483 observations or warning letters.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Risk Management in Clinical Trial Supply Chains

Posted on digi By digi

Clinical trial supply chains are inherently complex, spanning global depots, couriers, customs authorities, and investigator sites. Risks such as temperature excursions, customs delays, comparator shortages, and logistics vendor failures can directly affect patient safety and trial integrity. For US sponsors, the FDA requires that risks to investigational medicinal products (IMPs) are identified, mitigated, and documented as part of quality management systems (QMS). Failure to manage these risks can result in Form 483s, warning letters, and trial delays.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance

Sustainability in Clinical Trial Logistics

Posted on digi By digi

Clinical trial logistics traditionally focuses on compliance, safety, and supply continuity. Increasingly, regulators and stakeholders are emphasizing sustainability in the supply chain, requiring sponsors to minimize environmental impact without compromising compliance. US sponsors face scrutiny from FDA on proper waste disposal, packaging, and destruction processes, while EMA and WHO promote green initiatives across the supply chain. Incorporating sustainability aligns with global corporate responsibility goals and strengthens sponsor reputation in addition to regulatory compliance.

Click to read the full article.

Clinical Trial Logistics, Clinical Trial Operations & Compliance